دورية أكاديمية
أعرض في EDS

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.

التفاصيل البيبلوغرافية
العنوان: Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.
المؤلفون: Davar D; Cancer Immunology and Immunotherapeutics Program (CIIP), Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. davard@upmc.edu., Zarour HM; Cancer Immunology and Immunotherapeutics Program (CIIP), Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
المصدر: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2020; Vol. 2055, pp. 23-60.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Humana Press Country of Publication: United States NLM ID: 9214969 Publication Model: Print Cited Medium: Internet ISSN: 1940-6029 (Electronic) Linking ISSN: 10643745 NLM ISO Abbreviation: Methods Mol Biol Subsets: MEDLINE
أسماء مطبوعة: Publication: Totowa, NJ : Humana Press
Original Publication: Clifton, N.J. : Humana Press,
مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*pharmacology , Costimulatory and Inhibitory T-Cell Receptors/*metabolism , Neoplasms/*immunology, Animals ; Antineoplastic Agents, Immunological/therapeutic use ; Costimulatory and Inhibitory T-Cell Receptors/antagonists & inhibitors ; Costimulatory and Inhibitory T-Cell Receptors/chemistry ; Drug Development ; Humans ; Neoplasms/drug therapy ; Signal Transduction/drug effects
مستخلص: Tumor development is characterized by the accumulation of mutational and epigenetic changes that transform normal cells and survival pathways into self-sustaining cells capable of untrammeled growth. Although multiple modalities including surgery, radiation, and chemotherapy are available for the treatment of cancer, the benefits conferred are often limited. The immune system is capable of specific, durable, and adaptable responses. However, cancers hijack immune mechanisms such as negative regulatory checkpoints that have evolved to limit inflammatory and immune responses to thwart effective antitumor immunity. The development of monoclonal antibodies against inhibitory receptors expressed by immune cells has produced durable responses in a broad array of advanced malignancies and heralded a new dawn in the cancer armamentarium. However, these remarkable responses are limited to a minority of patients and indications, highlighting the need for more effective and novel approaches. Preclinical and clinical studies with immune checkpoint blockade are exploring the therapeutic potential antibody-based therapy targeting multiple inhibitory receptors. In this chapter, we discuss the current understanding of the structure, ligand specificities, function, and signaling activities of various inhibitory receptors. Additionally, we discuss the current development status of various immune checkpoint inhibitors targeting these negative immune receptors and highlight conceptual gaps in knowledge.
References: J Clin Oncol. 2015 Jun 10;33(17):1889-94. (PMID: 25667295)
Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8259-63. (PMID: 8367491)
Nature. 2014 Nov 27;515(7528):577-81. (PMID: 25428507)
J Exp Med. 1990 May 1;171(5):1393-405. (PMID: 1692078)
Nature. 2015 Jan 15;517(7534):386-90. (PMID: 25363763)
Eur J Immunol. 2001 Jul;31(7):2042-50. (PMID: 11449357)
Cell Rep. 2018 Apr 3;23(1):39-49. (PMID: 29617671)
Nat Immunol. 2011 Jun;12(6):492-9. (PMID: 21739672)
J Immunother Cancer. 2013 Jul 15;1:10. (PMID: 24829747)
Mol Cell Biol. 1994 May;14(5):3392-402. (PMID: 8164687)
Oncoimmunology. 2018 Feb 1;7(5):e1424677. (PMID: 29721390)
Cell Mol Immunol. 2018 May;15(5):438-446. (PMID: 29375120)
Nat Immunol. 2001 Dec;2(12):1109-16. (PMID: 11725301)
J Clin Invest. 2017 Aug 1;127(8):2930-2940. (PMID: 28650338)
J Immunol. 2009 May 1;182(9):5240-9. (PMID: 19380770)
Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144)
J Clin Oncol. 2013 Feb 10;31(5):616-22. (PMID: 23295794)
J Immunol. 2008 Apr 1;180(7):4409-14. (PMID: 18354161)
Eur J Immunol. 1994 Dec;24(12):3216-21. (PMID: 7805750)
J Exp Med. 1992 Aug 1;176(2):327-37. (PMID: 1380059)
J Exp Med. 2013 Apr 8;210(4):757-74. (PMID: 23530125)
N Engl J Med. 2003 Jan 16;348(3):203-13. (PMID: 12529460)
Nat Commun. 2015 Mar 26;6:6692. (PMID: 25809635)
Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531)
Eur J Immunol. 2003 Oct;33(10):2706-16. (PMID: 14515254)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Cancer Immunol Res. 2013 Jul;1(1):32-42. (PMID: 24777248)
J Exp Med. 1999 Aug 2;190(3):355-66. (PMID: 10430624)
J Exp Med. 2001 Apr 2;193(7):839-46. (PMID: 11283156)
J Exp Med. 1997 Nov 17;186(10):1645-53. (PMID: 9362525)
J Immunol. 1998 Oct 15;161(8):4058-65. (PMID: 9780176)
Cell. 2017 Sep 7;170(6):1120-1133.e17. (PMID: 28803728)
J Immunol. 2009 Feb 15;182(4):1885-91. (PMID: 19201841)
Science. 1993 Nov 5;262(5135):907-9. (PMID: 7694362)
Oncoimmunology. 2016 Nov 8;5(12):e1254855. (PMID: 28123898)
Front Immunol. 2018 Jul 30;9:1774. (PMID: 30105035)
Cancer Immunol Res. 2015 Dec;3(12):1344-55. (PMID: 26253731)
Eur J Immunol. 2011 Apr;41(4):902-15. (PMID: 21416464)
Curr Opin Immunol. 1997 Oct 1;9(5):681-3. (PMID: 9438857)
Eur J Immunol. 2008 Jan;38(1):40-7. (PMID: 18095376)
Cancer Cell. 2018 Apr 9;33(4):649-663.e4. (PMID: 29576375)
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5. (PMID: 2164219)
Sci Signal. 2012 Jun 26;5(230):ra46. (PMID: 22740686)
Immunity. 1994 Aug;1(5):405-13. (PMID: 7882171)
Cell. 1991 Sep 6;66(5):1037-49. (PMID: 1889086)
J Immunol. 2007 May 15;178(10):6073-82. (PMID: 17475832)
J Immunol. 2002 May 15;168(10):5070-8. (PMID: 11994459)
Cancer Res. 2009 Nov 15;69(22):8693-9. (PMID: 19861533)
Sci Rep. 2017 May 3;7(1):1485. (PMID: 28469254)
J Clin Invest. 2015 May;125(5):2046-58. (PMID: 25866972)
J Immunol. 2005 Mar 15;174(6):3377-85. (PMID: 15749870)
Blood. 2008 Aug 15;112(4):1175-83. (PMID: 18523152)
J Biol Chem. 2012 Mar 16;287(12):9429-40. (PMID: 22262842)
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. (PMID: 23032743)
JCI Insight. 2018 Jul 26;3(14):. (PMID: 30046006)
Nat Immunol. 2009 Jan;10(1):48-57. (PMID: 19011627)
Cancer Discov. 2016 Dec;6(12):1366-1381. (PMID: 27683557)
J Clin Invest. 2010 Dec;120(12):4546-57. (PMID: 21084749)
Cancer Res. 2014 Apr 1;74(7):1924-32. (PMID: 24691993)
Cell Death Differ. 2013 Mar;20(3):456-64. (PMID: 23154388)
Immunogenetics. 1997;47(1):96-8. (PMID: 9382927)
J Clin Invest. 2014 May;124(5):2246-59. (PMID: 24667641)
Science. 1995 Nov 10;270(5238):985-8. (PMID: 7481803)
Immunity. 2019 Jan 15;50(1):181-194.e6. (PMID: 30635236)
Immunity. 2000 Sep;13(3):313-22. (PMID: 11021529)
Biochem Biophys Res Commun. 2000 Mar 5;269(1):279-83. (PMID: 10694513)
Science. 2017 Mar 31;355(6332):1428-1433. (PMID: 28280247)
Science. 2008 Oct 10;322(5899):271-5. (PMID: 18845758)
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. (PMID: 19815499)
Eur J Immunol. 2009 Mar;39(3):695-703. (PMID: 19197944)
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71. (PMID: 9707601)
Cancer Metastasis Rev. 2008 Jun;27(2):179-92. (PMID: 18286234)
Nat Immunol. 2005 Dec;6(12):1245-52. (PMID: 16286920)
J Exp Med. 2000 Jul 17;192(2):295-302. (PMID: 10899916)
Cancer Cell. 2018 Jun 11;33(6):1033-1047.e5. (PMID: 29894690)
Cancer Discov. 2017 Feb;7(2):188-201. (PMID: 27903500)
Biochem Biophys Res Commun. 2006 Dec 15;351(2):571-6. (PMID: 17069754)
J Exp Med. 2010 Sep 27;207(10):2175-86. (PMID: 20819923)
Oncoimmunology. 2017 Nov 9;7(2):e1385690. (PMID: 29308307)
PLoS One. 2012;7(10):e47648. (PMID: 23112829)
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8. (PMID: 20679213)
Nat Cell Biol. 1999 Aug;1(4):193-9. (PMID: 10559916)
Cancer Res. 2009 Oct 1;69(19):7747-55. (PMID: 19738077)
Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. (PMID: 29712685)
J Exp Med. 1995 Aug 1;182(2):459-65. (PMID: 7543139)
EMBO J. 2007 Jan 24;26(2):494-504. (PMID: 17245433)
Sci Rep. 2018 Nov 30;8(1):17512. (PMID: 30504845)
J Clin Invest. 2015 Nov 2;125(11):4053-62. (PMID: 26413872)
Lancet Oncol. 2010 Feb;11(2):155-64. (PMID: 20004617)
Cancer Immunol Immunother. 2009 Sep;58(9):1517-26. (PMID: 19259667)
Clin Cancer Res. 2013 Jan 15;19(2):393-403. (PMID: 23204132)
J Immunol. 2015 Feb 1;194(3):950-9. (PMID: 25539810)
Mol Cell Biol. 2011 Oct;31(19):3963-74. (PMID: 21807895)
Science. 1993 Nov 5;262(5135):909-11. (PMID: 7694363)
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13218-23. (PMID: 16131544)
Semin Immunol. 1998 Aug;10(4):329-47. (PMID: 9695189)
Biochem Biophys Res Commun. 2001 Nov 2;288(3):573-8. (PMID: 11676481)
Eur J Immunol. 2014 Sep;44(9):2703-2711. (PMID: 24838857)
Mol Cell Biol. 2005 Nov;25(21):9543-53. (PMID: 16227604)
Cancer Res. 2014 Feb 15;74(4):1045-55. (PMID: 24343228)
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253)
Clin Cancer Res. 2009 Oct 15;15(20):6446-53. (PMID: 19808874)
Cancer Res. 2012 Jan 15;72(2):430-9. (PMID: 22108823)
J Immunol. 2008 May 1;180(9):5916-26. (PMID: 18424711)
Immunity. 2007 Mar;26(3):311-21. (PMID: 17363302)
J Exp Med. 2016 Feb 8;213(2):167-76. (PMID: 26755705)
Cancer Cell. 2018 Jan 8;33(1):60-74.e6. (PMID: 29316433)
Nature. 1987 Jul 16-22;328(6127):267-70. (PMID: 3496540)
Nature. 2017 May 4;545(7652):60-65. (PMID: 28397821)
J Clin Invest. 2006 Jul;116(7):1935-45. (PMID: 16778987)
Trends Immunol. 2015 Dec;36(12):760-762. (PMID: 26596798)
Nat Immunol. 2012 Sep;13(9):832-42. (PMID: 22842346)
Immunity. 2010 Sep 24;33(3):326-39. (PMID: 20870175)
PLoS One. 2013 Oct 30;8(10):e77992. (PMID: 24205057)
Clin Cancer Res. 2010 Feb 1;16(3):1042-8. (PMID: 20086001)
J Immunol. 2010 Feb 15;184(4):1918-30. (PMID: 20083673)
J Exp Med. 2013 Aug 26;210(9):1695-710. (PMID: 23897981)
Immunogenetics. 1994;39(3):213-7. (PMID: 7506235)
Nature. 2016 Sep 15;537(7620):417-421. (PMID: 27501248)
N Engl J Med. 2011 Jun 30;364(26):2517-26. (PMID: 21639810)
Eur J Med Genet. 2015 Oct;58(10):509-25. (PMID: 26341048)
J Exp Med. 2012 Jun 4;209(6):1201-17. (PMID: 22641383)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Cell. 1989 Mar 10;56(5):855-65. (PMID: 2538245)
Cancer Res. 2012 Feb 15;72(4):887-96. (PMID: 22205715)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34. (PMID: 19202079)
J Immunol. 2011 Feb 1;186(3):1338-42. (PMID: 21199897)
Cancer Res. 2014 Apr 1;74(7):1933-44. (PMID: 24691994)
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5336-41. (PMID: 12697896)
Cell Rep. 2015 Sep 29;12(12):1978-85. (PMID: 26365186)
Cancer Discov. 2016 Feb;6(2):202-16. (PMID: 26645196)
J Clin Oncol. 2012 Jul 20;30(21):2678-83. (PMID: 22711850)
Annu Rev Immunol. 2006;24:65-97. (PMID: 16551244)
J Biol Chem. 2014 Jun 20;289(25):17647-57. (PMID: 24817116)
J Immunol. 2005 Nov 1;175(9):6169-76. (PMID: 16237114)
Nature. 2002 Jan 31;415(6871):536-41. (PMID: 11823861)
Clin Cancer Res. 2016 Apr 15;22(8):1856-64. (PMID: 27084739)
Nat Immunol. 2005 Jan;6(1):90-8. (PMID: 15568026)
Cancer Cell. 2014 Dec 8;26(6):923-937. (PMID: 25465800)
J Immunol. 2002 Nov 15;169(10):5392-5. (PMID: 12421911)
PLoS One. 2012;7(2):e30676. (PMID: 22363469)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Exp Med. 2010 Sep 27;207(10):2187-94. (PMID: 20819927)
J Immunol. 2006 Oct 1;177(7):4376-83. (PMID: 16982872)
J Exp Med. 2009 Dec 21;206(13):3015-29. (PMID: 20008522)
Immunity. 1996 Jun;4(6):535-43. (PMID: 8673700)
Oncoimmunology. 2015 Mar 16;4(8):e1014246. (PMID: 26405566)
Hum Pathol. 2010 Oct;41(10):1486-94. (PMID: 20656318)
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. (PMID: 18818309)
J Immunother. 2008 Oct;31(8):781-91. (PMID: 18779741)
Immunity. 1999 Oct;11(4):483-93. (PMID: 10549630)
J Exp Med. 2000 Jul 17;192(2):303-10. (PMID: 10899917)
Science. 1998 Dec 18;282(5397):2263-6. (PMID: 9856951)
Nature. 2015 Jul 9;523(7559):231-5. (PMID: 25970248)
J Biol Chem. 2005 Nov 25;280(47):39553-61. (PMID: 16169851)
Science. 2011 Apr 29;332(6029):600-3. (PMID: 21474713)
Cell. 2016 Oct 6;167(2):397-404.e9. (PMID: 27667683)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
Nat Med. 2012 Sep;18(9):1394-400. (PMID: 22863785)
Eur J Immunol. 2003 Apr;33(4):970-9. (PMID: 12672063)
Eur J Immunol. 2002 Aug;32(8):2255-63. (PMID: 12209638)
Exp Hematol. 2018 Apr;60:47-56.e1. (PMID: 29353075)
Eur J Immunol. 2005 Jul;35(7):2081-8. (PMID: 15971272)
J Exp Med. 2008 Jun 9;205(6):1463-76. (PMID: 18519647)
Science. 1996 May 24;272(5265):1170-3. (PMID: 8638161)
Cell. 2019 Jan 10;176(1-2):334-347.e12. (PMID: 30580966)
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. (PMID: 25964334)
Mol Med Rep. 2018 Aug;18(2):1465-1472. (PMID: 29845203)
Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936)
J Exp Med. 2008 Nov 24;205(12):2763-79. (PMID: 19001139)
معلومات مُعتمدة: P50 CA121973 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: BTLA; CTLA-4; Immunotherapy; Inhibitory receptors; LAG-3; PD-1; TIGIT; TIM-3; VISTA
المشرفين على المادة: 0 (Antineoplastic Agents, Immunological)
0 (Costimulatory and Inhibitory T-Cell Receptors)
تواريخ الأحداث: Date Created: 20190911 Date Completed: 20201109 Latest Revision: 20210101
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7382898
DOI: 10.1007/978-1-4939-9773-2_2
PMID: 31502146
قاعدة البيانات: MEDLINE
الوصف
تدمد:1940-6029
DOI:10.1007/978-1-4939-9773-2_2